Baiyunshan Pharmaceutical To Lead Establishment Of New Drug Innovation Center
This article was originally published in PharmAsia News
Executive Summary
Helmed by the Guangdong government, leading pharmaceutical companies in the province are jointly investing RMB 100 million ($14.5 million) to set up a new drug innovation company and a privately operated non-commercial drug innovation center in southern China. Baiyunshan Pharmaceutical intends to lead the establishment of the new firm and will raise RMB 5 million independently to secure 5 million shares or 5 percent of the entity. Baiyunshan believes the investment will bring new development opportunities: the understanding and acquisition of latest R&D information and dynamics of the industry; the sharing of the core technology platform of the new drug center; and priority in getting the center's R&D transfer rights. (Click here for more - Chinese Language)